Table 2.
BP, Antihypertensive Use, and Mean Follow‐Up Time in INVEST‐GENES Participants at Visit Prior to Event or Censoring
| European Americans (n=904) | Hispanics (n=837) | |||
|---|---|---|---|---|
| Controlled HTN (n=623) | RHTN (n=281) | Controlled HTN (n=602) | RHTN (n=235) | |
| SBP, mm Hg, mean±SD | 125.8±9.4 | 141.0±18.1* | 123.6±8.6 | 142.2±16.2* |
| DBP, mm Hg, mean±SD | 73.4±7.5 | 77.0±11.3* | 76.1±6.5 | 83.1±10.1* |
| Number of antihypertensive drugs, mean±SD | 2.2±0.8 | 3.6±0.5* | 2.1±0.8 | 3.5±0.5* |
| Class of antihypertensive drugs | ||||
| Calcium channel blocker | 233 (37.4%) | 106 (37.7%) | 246 (40.9%) | 94 (40%) |
| β‐blocker | 262 (42.1%) | 153 (54.5%)* | 253 (42.0%) | 133 (56.6%)* |
| Thiazide diuretic | 380 (61%) | 251 (89.2%)* | 340 (56.5%) | 214 (91.1%)* |
| ACE inhibitor | 376 (60.4%) | 256 (91.1%)* | 333 (55.3%) | 220 (93.6%)* |
| Others | 73 (11.7%) | 131 (46.6%)* | 38 (6.3%) | 73 (31.1%)* |
| Mean follow‐up time, years, mean±SD | 2.9±0.9 | 2.8±1.0 | 2.5±0.5 | 2.2±0.6* |
Numbers represent n (%), unless otherwise specified. ACE indicates angiotensin‐converting enzyme; BP, blood pressure; DBP, diastolic blood pressure; HTN, hypertension; INVEST‐GENES, INternational VErapamil SR Trandolapril Study–GENEtic Substudy; RHTN, resistant hypertension; SBP, systolic blood pressure.
*
P≤0.05 compared to Controlled HTN European Americans.
*
P≤0.05 compared to Controlled HTN Hispanics.